Untreated people with the HFE C282Y mutation in both copies face a 20 to 30% risk of developing cirrhosis. In those with hemochromatosis related cirrhosis, hepatocellular carcinoma risk is about 200 times higher than in the general population. Other major complications also cluster in predictable ranges, including diabetes in 30 to 50% of symptomatic patients at diagnosis and cardiac arrhythmia accounting for 30% of mortality.
Key Takeaways
- Cirrhosis develops in 20-30% of untreated C282Y homozygotes
- Hepatocellular carcinoma risk 200-fold increased in HH cirrhosis vs general population
- Diabetes mellitus in 30-50% of symptomatic HH patients at diagnosis
- The C282Y mutation in HFE gene accounts for 80-90% of hereditary hemochromatosis cases in populations of Northern European origin
- H63D mutation in HFE is a common polymorphism with allele frequency of 15-20% in Europeans but rarely pathogenic alone
- Compound heterozygosity for C282Y/H63D occurs in 2-5% of Caucasians and increases iron absorption mildly
- Hereditary hemochromatosis affects approximately 1 in 200 to 1 in 300 individuals of Northern European descent as homozygous for the C282Y mutation in the HFE gene
- In the United States, the carrier frequency for HFE C282Y mutation is about 1 in 10 among Caucasians
- Global prevalence of hereditary hemochromatosis type 1 (HFE-related) is estimated at 0.3-0.5% in populations of European ancestry
- Transferrin saturation >45% is first diagnostic marker, present in 90% of C282Y homozygotes before age 50
- Serum ferritin >1000 ng/mL indicates significant iron overload in hemochromatosis
- Liver biopsy shows grade 4 siderosis (4+ iron in hepatocytes) in 80% of untreated HH patients
- Phlebotomy response: ferritin decline 30-50 mg/L per 500 mL blood removed
- Therapeutic phlebotomy targets ferritin <50 ng/mL, reducing mortality by 50%
- Iron chelation with deferasirox 20-30 mg/kg/day normalizes ferritin in 70% of transfusion-dependent HH
Early phlebotomy prevents severe organ damage, cutting cirrhosis and cancer risk in hereditary hemochromatosis.
Related reading
01 · Category
Complications And Prognosis23 stats
01
Cirrhosis develops in 20-30% of untreated C282Y homozygotes
02
Hepatocellular carcinoma risk 200-fold increased in HH cirrhosis vs general population
03
Diabetes mellitus in 30-50% of symptomatic HH patients at diagnosis
04
HCC annual incidence 2-4% in cirrhotic HH
05
Cardiac arrhythmia death accounts for 30% of mortality in untreated HH
06
Hypogonadotropic hypogonadism leads to infertility in 25% untreated men
07
Osteoporosis fracture risk 3-fold higher in HH men under 60
08
Dilated cardiomyopathy in 15% of advanced untreated cases, ejection fraction <40%
09
5-year survival post-HCC diagnosis in HH is 20%
10
Arthropathy progresses despite treatment in 20-30%, requiring joint replacement in 5%
11
Liver failure mortality reduced from 60% to 10% with early phlebotomy
12
Parkinson's disease risk increased 2-fold in HH due to brain iron
13
Impotence persists in 20% despite treatment if longstanding
14
Secondary hemochromatosis from transfusions increases cardiac death by 50%
15
Cholelithiasis in 20-30% due to cirrhosis
16
Porphyria cutanea tarda complicates 20% of HH cases, blisters heal slower
17
10-year life expectancy normalized with treatment if no cirrhosis
18
HCC multifocal in 40% of HH cirrhotics at diagnosis
19
Hearing loss bilateral severe in 10% advanced cases
20
Splenomegaly with hypersplenism in 15% cirrhotic HH
21
Esophageal varices bleed risk 20-30% per year untreated cirrhosis
22
Neurodegeneration mimics ALS in rare advanced iron brain deposition
23
Diabetes insulin dependence in 60% of HH cases, nephropathy risk +2x
Interpretation
Complications And Prognosis Interpretation
In untreated hemochromatosis, prognosis is shaped by major organ complications with cirrhosis developing in 20 to 30% of C282Y homozygotes and hepatocellular carcinoma occurring at a 200-fold higher risk, while cardiac arrhythmias account for 30% of deaths, diabetes appears in 30 to 50% of symptomatic cases, and fertility is impaired in 25% of untreated men due to hypogonadotropic hypogonadism.
More related reading
02 · Category
Genetics And Molecular Biology25 stats
01
The C282Y mutation in HFE gene accounts for 80-90% of hereditary hemochromatosis cases in populations of Northern European origin
02
H63D mutation in HFE is a common polymorphism with allele frequency of 15-20% in Europeans but rarely pathogenic alone
03
Compound heterozygosity for C282Y/H63D occurs in 2-5% of Caucasians and increases iron absorption mildly
04
Type 2A hemochromatosis is caused by mutations in HJV (hemojuvelin) gene on chromosome 1q21
05
Ferroportin (SLC40A1) gene mutations cause type 4 hemochromatosis with autosomal dominant inheritance
06
HAMP gene (hepcidin) mutations lead to type 2B juvenile hemochromatosis, autosomal recessive
07
TFR2 gene mutations cause type 3 hemochromatosis, rare, autosomal recessive, chromosome 7q22
08
Neonatal hemochromatosis is associated with maternal-fetal alloimmunity to alpha-1-antitrypsin, not primarily genetic
09
Over 40 pathogenic mutations identified in HFE gene, but C282Y is the most penetrant
10
S65C mutation in HFE is rare (allele frequency <0.5%) and associated with mild iron overload
11
Hepcidin, encoded by HAMP, is the master regulator of iron homeostasis, deficient in most hemochromatosis types
12
Matriptase-2 (TMPRSS6) loss-of-function mutations cause iron-refractory iron deficiency anemia, opposite of hemochromatosis, but relevant pathway
13
BMP6 mutations are linked to rare iron overload disorders resembling hemochromatosis
14
The C282Y mutation substitutes tyrosine for cysteine at position 282, disrupting HFE-beta2-microglobulin interaction
15
HJV acts as BMP co-receptor, enhancing hepcidin transcription; mutations abolish this
16
Ferroportin p.Val162del mutation causes classical type 4B hemochromatosis with iron accumulation in Kupffer cells
17
Genetic penetrance varies; C282Y homozygotes have 2-4 fold increased transferrin saturation
18
Rare HFE mutations like I105T and G93R are associated with increased ferritin without C282Y
19
Polygenic inheritance influences penetrance, with TMPRSS6 variants modulating HFE effects
20
Autosomal recessive inheritance for HFE-related HH; both alleles must be mutated for disease
21
H63D/C282Y compound heterozygotes have 1.5-2x normal ferritin in 20-30% of cases
22
Next-generation sequencing identifies novel variants in non-HFE hemochromatosis in 10% of unexplained cases
23
Mouse models: Hfe knockout recapitulates iron overload phenotype
24
Hepcidin knockout mice die of iron overload by 9 months
25
Genetic testing for HFE detects 90% of HH cases in appropriate populations
Interpretation
Genetics And Molecular Biology Interpretation
In the genetics and molecular biology of hemochromatosis, the HFE C282Y mutation explains 80 to 90 percent of hereditary cases in Northern Europeans, while other HFE variants like H63D usually cause little risk alone and only account for a small 2 to 5 percent share of disease when combined as C282Y/H63D, with rarer forms tied to specific gene defects such as HJV for type 2A and SLC40A1 or HAMP for later types.
More related reading
03 · Category
Prevalence And Epidemiology30 stats
01
Hereditary hemochromatosis affects approximately 1 in 200 to 1 in 300 individuals of Northern European descent as homozygous for the C282Y mutation in the HFE gene
02
In the United States, the carrier frequency for HFE C282Y mutation is about 1 in 10 among Caucasians
03
Global prevalence of hereditary hemochromatosis type 1 (HFE-related) is estimated at 0.3-0.5% in populations of European ancestry
04
Among blood donors in the US, 0.4% are homozygous for C282Y, indicating a carrier rate of around 12%
05
In Australia, the prevalence of C282Y homozygosity is 0.48% in men and 0.32% in women
06
Hemochromatosis is more common in men, with a male-to-female ratio of about 2:1 for clinical penetrance
07
In Ireland, the frequency of C282Y homozygotes is as high as 1 in 83
08
Non-HFE hemochromatosis accounts for less than 5% of cases in Europe but up to 20% in other populations
09
Juvenile hemochromatosis prevalence is rare, estimated at 1 in 1,000,000
10
In African Americans, HFE C282Y homozygosity is only 0.00014%
11
The HFE C282Y mutation originated about 60 generations ago in Celtic populations
12
Penetrance of C282Y homozygosity is 80% biochemical but only 25-30% clinical in men
13
In Canada, screening studies show 1 in 227 Caucasians are C282Y homozygotes
14
Neonatal screening detects hemochromatosis genotypes at 0.25-0.5% in US newborns of European descent
15
In Southern Europe, C282Y allele frequency drops to 5-10% compared to 10-15% in the north
16
African iron overload (Bantu siderosis) affects up to 10% of rural black South Africans
17
In porphyria cutanea tarda patients, 70-90% have HFE mutations contributing to iron overload
18
Type 2A hemochromatosis (HJV mutations) prevalence is 1-2 per million in Europe
19
Ferroportin disease (type 4) represents 2-10% of hemochromatosis cases in referral centers
20
In Asia, TMPRSS6 mutations linked to iron overload in 1-2% of cases mimicking hemochromatosis
21
US annual incidence of clinically diagnosed hemochromatosis is about 1 per 10,000
22
Women with C282Y homozygosity have 50% lower risk of clinical disease due to menstruation
23
In Utah population database, lifetime risk for C282Y homozygotes developing iron overload is 38% in men
24
Brazilian studies show C282Y homozygosity at 0.24% in general population
25
In French populations, H63D homozygosity prevalence is 1.5%
26
Neonatal hemochromatosis incidence is 1 in 100,000 live births
27
Alcoholics have 25-50% prevalence of HFE mutations
28
In Sardinia, HAMP mutations (type 2B) are found in 1:100,000
29
Global non-alcoholic fatty liver disease patients have 30% HFE mutation rate
30
In Iceland, C282Y frequency is 8.3% allele rate
Interpretation
Prevalence And Epidemiology Interpretation
Across populations of European ancestry, hereditary hemochromatosis type 1 is present in about 0.3 to 0.5 percent, with carrier frequencies near 1 in 10 for the HFE C282Y mutation and a higher clinical penetrance in men at roughly a 2 to 1 male to female ratio.
More related reading
04 · Category
Symptoms And Diagnosis29 stats
01
Transferrin saturation >45% is first diagnostic marker, present in 90% of C282Y homozygotes before age 50
02
Serum ferritin >1000 ng/mL indicates significant iron overload in hemochromatosis
03
Liver biopsy shows grade 4 siderosis (4+ iron in hepatocytes) in 80% of untreated HH patients
04
MRI liver iron concentration >200 μmol/g predicts cirrhosis risk with 85% accuracy
05
Elevated transferrin saturation with normal ferritin occurs in 60% of presymptomatic C282Y homozygotes
06
Fatigue is reported in 75-90% of symptomatic hemochromatosis patients at diagnosis
07
Arthralgia, especially in metacarpophalangeal joints 2 and 3, affects 40-60% of patients
08
Hypogonadism due to pituitary iron deposition occurs in 30-50% of untreated men
09
Echocardiography shows diastolic dysfunction in 25% of asymptomatic HH patients
10
Genetic testing positive for C282Y homozygosity has 95% specificity for HH in high-risk populations
11
Fasting transferrin saturation >60% in men or >50% in women prompts HFE testing per AASLD guidelines
12
Serum ferritin rises at 20-30 μg/L per year in untreated C282Y homozygotes
13
Bronze diabetes (skin pigmentation + diabetes) classic triad in only 10-20% at presentation
14
Abnormal liver enzymes (ALT/AST >2x ULN) in 20-30% of presymptomatic HH
15
Superficial siderosis of skin biopsy confirms diagnosis in ambiguous cases
16
FibroScan liver stiffness >12 kPa indicates advanced fibrosis with 90% PPV in HH
17
Oral glucose tolerance test abnormal in 40% of HH patients without known diabetes
18
Polysomnography shows sleep apnea in 50% of symptomatic HH males
19
DEXA scan reveals osteoporosis in 25-40% of men with HH at diagnosis
20
Electrocardiogram QT prolongation in 15% due to iron cardiomyopathy
21
HLA typing historically used; A3-B14 haplotype in 80% of HH patients pre-HFE discovery
22
Serum iron >200 μg/dL with 90% saturation diagnostic in context of symptoms
23
Hepatic iron index (ferritin/age / liver iron conc) >1.9 confirms HH over secondary overload
24
Brain MRI shows basal ganglia hypointensity in 30% of advanced HH cases
25
Impotence reported by 45% of men at diagnosis, resolving with phlebotomy in 60%
26
Amenorrhea in 20-30% of premenopausal women with untreated HH
27
Audiometry reveals sensorineural hearing loss in 30% of HH patients
28
Fasting serum hepcidin <20 ng/mL in 95% of HH patients vs normals
29
Erythrocyte mean corpuscular volume low in 10% due to concurrent deficiencies
Interpretation
Symptoms And Diagnosis Interpretation
For symptom and diagnosis of hemochromatosis, a transferrin saturation above 45% appears in about 90% of C282Y homozygotes before age 50 and can be present with normal ferritin in 60% of presymptomatic cases, while classic presentation often includes fatigue in 75 to 90% and advanced liver iron findings such as grade 4 siderosis in 80% of untreated patients.
More related reading
05 · Category
Treatment And Management26 stats
01
Phlebotomy response: ferritin decline 30-50 mg/L per 500 mL blood removed
02
Therapeutic phlebotomy targets ferritin <50 ng/mL, reducing mortality by 50%
03
Iron chelation with deferasirox 20-30 mg/kg/day normalizes ferritin in 70% of transfusion-dependent HH
04
Weekly phlebotomy of 500 mL removes 250 mg iron, sufficient for most adults
05
MRI monitoring post-phlebotomy shows LIC reduction of 40-60% in 12 months
06
Erythropoietin 10,000 U/week allows intensified phlebotomy in 80% without anemia
07
Liver transplant survival 5-year rate 80% in decompensated HH cirrhosis
08
Deferoxamine 40 mg/kg/night subcutaneous chelation mobilizes 30-50 mg iron/day
09
Family screening with genetic testing identifies 25% at-risk relatives needing intervention
10
Phlebotomy prevents diabetes progression in 60% of impaired glucose tolerant HH patients
11
Low-iron diet (<8 mg/day) augments phlebotomy efficacy by 20-30%
12
Vitamin C 500 mg/day enhances iron excretion during chelation by 2-3 fold
13
Tamoxifen reduces ferritin by 20% in HH with breast cancer comorbidity, anecdotal
14
Maintenance phlebotomy every 2-3 months keeps ferritin normal in 90% long-term
15
Deferiprone 75 mg/kg/day oral chelator effective in cardiac iron overload in HH
16
Early phlebotomy before ferritin >1000 prevents cirrhosis in 95% of cases
17
Hepatitis C co-infection requires antiviral therapy post-iron depletion, SVR 60%
18
Testosterone replacement normalizes hypogonadism in 70% after iron removal
19
Bisphosphonates improve BMD in HH osteoporosis post-phlebotomy, +5-10% at 2 years
20
CPAP for sleep apnea improves fatigue scores by 40% in HH patients
21
Ursodeoxycholic acid no benefit in HH cholestasis
22
Experimental hepcidin mimetics in trials reduce iron absorption by 70%
23
Phlebotomy reduces ALT by 50% within 6 months in 80% of patients
24
Insurance coverage for genetic testing improves screening compliance by 30%
25
Cirrhosis risk drops from 40% to <5% with phlebotomy before age 40
26
HCC surveillance with US/AFP every 6 months post-iron depletion, detects 70% early
Interpretation
Treatment And Management Interpretation
Under treatment and management, therapeutic phlebotomy and iron control can drive ferritin down 30 to 50 mg/L per 500 mL and target ferritin below 50 ng/mL, with reported mortality reduction of 50%, while chelation with deferasirox normalizes ferritin in 70% of transfusion dependent patients.
report visual · Breakdown
Key Outcomes in Hemochromatosis (Untreated vs Treated)
Untreated HH carries high organ complication rates, while early phlebotomy sharply lowers progression and cirrhosis risk.
60%
Liver failure mortality reduced from 60% to 10% with early phlebotomy
40%
Cirrhosis risk drops from 40% to <5% with phlebotomy before age 40
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Hemochromatosis Statistics. Gitnux. https://gitnux.org/hemochromatosis-statistics
MLA
Rachel Svensson. "Hemochromatosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hemochromatosis-statistics.
Chicago
Rachel Svensson. 2026. "Hemochromatosis Statistics." Gitnux. https://gitnux.org/hemochromatosis-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level